The movement of physiologic nucleosides and nucleoside analogue drugs across biological membranes is mediated by nucleoside transport proteins. In cancer, nucleoside transporters have an important role in maintaining the hyperproliferative state of tumours and are important targets for diagnostic and therapeutic agents in the detection, treatment and monitoring of cancers. The nucleoside-based probe 3ꞌ-deoxy-3ꞌ- 
in the treatment of cancer and viral diseases. In the case of cancer, nucleoside transport has an important role in maintaining the hyperproliferative state of most tumours and is therefore an important target for diagnostic and therapeutic agents in the detection, treatment and monitoring of cancers. Indeed, the clinical efficacy of anticancer nucleoside analogue drugs depends on a complex interdependence of transporters mediating entry of drugs into cells, efflux mechanisms that remove drugs from intracellular compartments and cellular metabolism to active metabolites [1] [2] [3] [4] [5] [6] .
In humans, two solute carrier gene families (SLC28 and SLC29) are foremost responsible for the uptake of nucleosides and nucleoside analogues into cells [7] [8] [9] [10] [11] . The SLC28 human concentrative nucleoside transporter (hCNT) family contains three members that mediate unidirectional transport of nucleosides into cells against their concentration gradient driven by a downward sodium
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Nucleoside transporters in PET imaging of proliferating cancer cells using 3ꞌ-deoxy-3ꞌ-[ Saidijam et al. gradient that moves in the same direction (symport). hCNTs are high affinity transporters found predominantly in intestinal and renal epithelia and also in other specialised cell types. hCNT1 and hCNT2 have preferences for pyrimidine and purine nucleosides, respectively, whilst hCNT3 has broad nucleoside selectivity [12] [13] [14] [15] . The SLC29 human equilibrative nucleoside transporter (hENT) family contains four members that mediate bidirectional unenergised transport of nucleosides down their concentration gradient (facilitated diffusion). hENTs are widely distributed in most, possibly all, cell types and hENTs 1-3 have broad specificity for both purine and pyrimidine nucleosides. hENT4, also known as PMAT, is uniquely selective for adenosine and also transports a variety of organic cations [16] [17] [18] [19] [20] . Some nucleosidederived drugs can also interact with and be translocated by members of the SLC22 gene family, which include organic anion transporters (OATs), organic cation transporters (OCTs) and organic carnitine and zwitterion transporters (OCTNs) [9, [21] [22] [23] [24] [25] .
The pyrimidine nucleoside analogue gemcitabine (2',2'-difluorodeoxycytidine, trade name Gemzar) (1) is widely used as a first-line chemotherapeutic drug in the treatment of various cancers including bladder cancer, breast cancer, non-small cell lung cancer, ovarian cancer and pancreatic cancer. Unfortunately, there is often rapid development of either de novo or induced drug resistance, which significantly limits the effectiveness of gemcitabine chemotherapy.
Whilst the cytotoxic effects of gemcitabine are exerted following phosphorylation and then inhibition of DNA synthesis, it must first enter cells through nucleoside transporters, especially the ubiquitous hENT1. Hence, hENT1 expression and activity has been identified as an important prognostic biomarker in gemcitabine-treated cancers and therefore as a predictive biomarker of gemcitabine efficacy. This is particularly true of pancreatic cancer, where high expression of hENT1 is associated with increased overall survival and disease-free survival in patients treated with gemcitabine [26] [27] [28] [29] [30] . It therefore follows that a deficiency in hENT1 confers resistance to the cytotoxicity of gemcitabine [31] [32] [33] [34] and approaches have been explored to overcome hENT1 deficiency. For example, upregulation of hENT1 expression in pancreatic cell lines by indole-3-carbinol enhanced the efficacy of gemcitabine [35] . Functionalised lipophilic nanoparticles have also been developed for delivery of gemcitabine into cells that bypass nucleoside transporters [36, 37] . In addition to gemcitabine, other nucleoside analogues have been used and explored as chemotherapeutic drugs [38] [39] [40] [41] .
PET IMAGING USING 3ꞌ-DEOXY-3ꞌ-[
18 F]-FLUORO-L-THYMIDINE
Overview
Positron emission tomography (PET) is a non-invasive clinical nuclear medicine technique routinely used to produce two-or three-dimensional images of the body for diagnosing and monitoring a wide range of human diseases. The PET system detects pairs of gamma rays emitted indirectly by a short-lived positron emitting radionuclide (or radiotracer), which is introduced into the body on a biologically active molecule [42] . Because PET images directly reflect in vivo tissue physiology and metabolism, one of their foremost uses is in the detection of proliferating cancer cells and monitoring their response to treatments. Indeed, the early metabolic changes associated with cancers can be detected by PET imaging before more advanced morphologic changes are detected by anatomic imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI). This allows earlier diagnosis and earlier intervention with appropriate treatments that are more likely to have a successful outcome. By far the most commonly used radiotracer in PET imaging is 2-deoxy-2-[ 18 (Figure 1 ). TK1 is a key enzyme that is upregulated in cancer cells and, in agreement with separate studies [49, 50] , it is assumed that the concentration of [ 18 
F]FLT inside cells
is proportional to TK1 activity and therefore to cellular proliferation. One of the characteristics of tumour cells is an unchecked proliferation and it is important to measure the proliferation rate of cancer lesions to help differentiate benign from malignant tumours and to characterise malignant tumours amongst normal tissues. A further advantage of [ 18 F] FLT is that it is only a substrate for TK1 and not for mitochondrial TK2, making it a more specific radiotracer compared with other fluorinated nucleoside analogues for cellular proliferation. [52] [53] [54] [55] . Their improved method made minimal use of specialised materials and apparatus and included a threestep radiosynthesis producing [ 18 F] FLT with a radiochemical yield (at end of bombardment) of 13% and an end of synthesis yield of 7% over 94 minutes [56] . The method used a nosylate (4-nitrobenzenesulphonate) ester as the radiolabelling precursor
(12) that was synthesised in seven steps from thymidine (4) in an overall yield of 17% (Scheme 2). Nucleophilic displacement of (12) (14) and single neutral alumina column purification, a fully automated and simplified synthesis of [ 18 F] FLT produced an uncorrected radiochemical yield of 8.48 ± 0.93% (n = 5) in a total time of 68 ± 3 minutes and a radiochemical purity of >95% [58] . This method obviated the need for HPLC purification and the product was tested for safe levels of residual aluminium and DMSO. New radiolabelling precursors were assessed using different protecting groups at the 5ꞌ-hydroxyl position [trityl (Tr) and 4,4'-dimethoxytrityl (DMTr)] and different electrophilic centres at the 3ꞌ-carbon [methylsulfonyl (mesyl/Ms), p-toluenesulfonyl (tosyl/Ts) and 4-nitrobenzenesulfonyl (nosyl/Ns) groups]. These precursors also had 3-N-Boc-protection, which avoided use of CAN and the resultant precipitates, thus enabling use of an automated synthesis module (Scheme 3) [59] .
The nosylated precursors proved most successful for radiolabelling with 18 F and best results were obtained using [63] .
The 3-N-Boc-protected compound 15 remains the most commonly used radiolabelling precursor for [ 18 F ]FLT synthesis and is commercially available at GMP grade. Indeed, [ 18 F] FLT suitable for microPET studies has been efficiently synthesised from 15 using an electrowetting-ondielectric digital microfluidic chip [64] and an automated and efficient radiosynthesis of [ 18 F ]FLT using a low amount of 15 (5 mg) has been developed, achieving a corrected radiochemical yield of 54% in a time of 52 minutes [65] .
It is clear that the radiosynthesis of [ 18 F] FLT can lead to many complex and potentially toxic side-products. According to the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the NIH requires an [ 18 F] FLT radiochemical purity of no less than 95% and no more than 5 mcg of nonradioactive FLT and no more than 5 mcg of other UV-absorbing impurities http://interactive.snm.org/docs/PET_PROS/FLT_07-11-12%20Final.pdf. [ 18 F] FLT is therefore subject to stringent tests of quality control and biological assessment [66, 67] . (Figure 3) , it correlated better with immunohistochemistry Ki-67 values and was a more powerful predictor of tumour progression and survival [73] . More recently, a study investigating the performance of cellular metabolism imaging with [ 18 [81] . Radiation-induced fibrosarcoma-1 tumor-bearing mice, injected with the thymidylate synthase inhibitor 5-fluorouracil, were imaged by [
18 F]FLT PET 1 to 2 hours after treatment (Figure 4 ). Parallel measurements included whole-cell assays implicating a functional role for ENT1, in which there was an increase in ENT1-binding sites per cell from 49,110 in untreated cells to 73,142 (P = 0.03) in cells treated with 5-fluorouracil (10 g/ml, 2 hours), without a change in transporter affinity (P = 0.41). It was concluded that [ 18 F] FLT PET can measure thymidylate synthase inhibition as early as 1 to 2 hours after treatment with 5-fluorouracil by a mechanism involving redistribution of ENT1to the plasma membrane [81] . In a study specifically designed to investigate roles of human nucleoside transporters in uptake of FLT [82] , binding of FLT to transporters was initially monitored by its inhibitory effects on [ Figure 5B ). hENT1 and hENT2 produced higher transport capacities and lower apparent affinities than hCNT1 and hCNT3. The transport efficiency (Vmax/Km) was approximately 6-fold greater for hCNT1 and hCNT3 than for hENT1 and hENT2, suggesting that hCNT1 and hCNT3 transport [ 3 H]FLT more efficiently than hENT1 and hENT2 at lower (micromolar) concentrations [82] . A subsequent study investigated the importance of ENT1 for [ 18 F] FLT uptake in normal tissues and tumours [83] . ENT1-knockout (ENT1(-/-)) mice were compared with wild-type (ENT1(+/+)) mice using small-animal [ 18 thymidine levels were 1.65-fold higher in ENT1(-/-) mice than in ENT1(+/+) mice, whilst spleen tissue from ENT1(+/+) and ENT1(-/-) mice showed similar TK1 protein levels and significant staining of CNT1 and CNT3 [83] .
Human lung carcinoma cells transfected with pSUPER-producing short-hairpin RNA against hENT1 (A549-pSUPER-hENT1) displayed 0.45-fold hENT1 transcript levels and 0.68-fold [ 3 H]FLT uptake compared with cells transfected with a scrambled sequence with no homology to mammalian genes (A549-pSUPER-SC). Compared with A549-pSUPER-SC xenograft tumors, A549-pSUPER-hENT1 xenograft tumors displayed 0.76-fold %ID/g values (ex vivo gamma-counts) and 0.65-fold maximum SUV (PET image analysis) for [ 18 F ]FLT uptake at 1 h after tracer injection. Because loss of ENT1 activity significantly affected [ 18 F] FLT biodistribution in mice and [ 18 F] FLT uptake in xenograft tumors, it was concluded that ENT1 is an important mediator of [ 18 F] FLT uptake in normal tissues and tumours [83] .
A parallel study was performed to determine if FLT uptake is a predictor of gemcitabine uptake and/or toxicity in a panel of six different human pancreatic cancer cell lines (Capan-2, AsPC-1, BxPC-3, PL45, MIA PaCa-2 and PANC-1) [84] . Capan-2 cells displayed the lowest levels of extracellular NBMPR binding, FLT and gemcitabine uptake during short (1-45 seconds) and prolonged (1 hour) periods, and gemcitabine sensitivity. Exposure to NBMPR (inhibits only hENT1) or dilazep (inhibits hENT1 and hENT2) reduced FLT and gemcitabine uptake and gemcitabine sensitivity, with dilazep having greater effects than NBMPR. Gemcitabine permeation was primarily mediated by hENT1, and to a lesser extent by hENT2, whilst FLT permeation included a substantial component of passive diffusion [84] . In five out of six cell lines, correlations were observed between FLT and gemcitabine initial rates of uptake, gemcitabine uptake and gemcitabine toxicity, FLT uptake and gemcitabine toxicity, and ribonucleotide reductase subunit M1 expression and gemcitabine toxicity. Uptakes of FLT and gemcitabine were comparable for predicting gemcitabine toxicity in the tested pancreatic cancer cell lines, it was therefore concluded that [ 18 F ]FLT may provide clinically useful information about tumour gemcitabine transport capacity and sensitivity [84] .
In a study investigating the correlation of [ 18 Isolated human B-lymphobast cells, either proficient or deficient in TK1, were studied to show how metabolism and nucleoside transport influence uptake and retention of FLT [86] . Both influx and efflux of FLT were measured under conditions where concentrative and equilibrative transport could be distinguished. Whilst initial rates of FLT uptake were a function of both concentrative and equilibrative transporters, concentrative FLT transport dominated over equilibrative transport. Inhibition of hENT1 reduced FLT uptake, but there were no correlations between clonal variations in hENT1 levels and FLT uptake. TK1 was mandatory for the cellular concentration of FLT and uptake peaked after 60 minutes of incubation with FLT, followed by a decline in intracellular levels of FLT and its metbolites. Efflux was rapid and was associated with reductions in FLT and its metabolites [86] .
In a study examining the extent to which ENT1 levels vary in a proliferation-dependent manner in human A549 tumor cells grown as tumor xenografts in nude mice, [ 18 F] FLT uptake was measured in vivo using small animal PET and further examined ex vivo using autoradiography [87] . [87] .
A later study investigated whether uptake of [ 18 F ]FLT in newly diagnosed gliomas correlates with ENT1 mRNA expression, microvascular density (assessed by CD34 immunohistochemistry) and blood-brain barrier permeability [88] . In tumour lesions identified by increased [ 18 F] FLT uptake, dynamic analysis revealed correlations between the phosphorylation rate constant k3 and ENT1 expression, but there was no correlation between the kinetic parameters and CD34 score. Good correlation was observed between the gadolinium (Gd) enhancement score (evaluating blood-brain barrier breakdown) and ENT1 expression, CD34 score and Ki-67 index. It was therefore concluded that ENT1 expression might not reflect accumulation of [ 18 F] FLT in vivo due to blood-brain barrier permeability in glioma [88] .
TAS-102 is a recently developed orally administered combination chemotherapy drug composed of α,α,α-trifluorothymidine (TFT) and a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) in a 1:0.5 ratio. TAS-102 has especially been targeted at metastatic colorectal cancer [89] [90] [91] [92] [93] [94] . In the mechanism of action of TAS-102, TFT is intracellularly phosphorylated and then incorporated into DNA, which leads to DNA damage and cell cycle arrest. TPI is an inhibitor of thymidine phosphorylase that metabolises TFT, therefore increasing the bioavailability of TFT, and TPI is also an inhibitor of angiogenesis. hCNT1 has a major role in intestinal absorption of TFT and, when expressed in Xenopus laevis oocytes, uptake of TFT by hCNT1 has Km and Vmax values of 69.0 μM and 516 pmol/oocyte/30 min, respectively [95] .
In human colon cancer xenografts in mice, administration of TAS-102 imparted a decrease in cell viability and an increase in [ 18 F ]FLT have been developed, for which the most widely used radiolabelling precursor is the thymidine derivative 3-N-boc-5ꞌ-O-dimethoxytrityl-3ꞌ-Onosyl-thymidine.
[ 18 F] FLT enters proliferating cells through nucleoside transporters, which are also routes of entry into cells for anti-cancer and anti-viral nucleoside analogue drugs. The roles of nucleoside transporters, especially ENT1, in the cellular uptake of [ 18 F] FLT have been investigated. Further studies on structure-activity relationships and regulation of nucleoside transporters are necessary for improving the design and delivery of nucleoside analogue drugs and for ongoing developments in PET imaging of cancers and other diseases.
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